MARKET

KPTI

KPTI

Karyopharm Therapeutics Inc
NASDAQ
9.01
+1.64
+22.25%
Opening 15:33 02/12 EST
OPEN
6.72
PREV CLOSE
7.37
HIGH
9.94
LOW
6.72
VOLUME
2.19M
TURNOVER
--
52 WEEK HIGH
10.38
52 WEEK LOW
3.510
MARKET CAP
164.98M
P/E (TTM)
-0.6180
1D
5D
1M
3M
1Y
5Y
1D
Karyopharm (KPTI) Q4 2025 Earnings Call Transcript
The Motley Fool · 4h ago
Karyopharm Therapeutics Q4 Earnings Assessment
Benzinga · 6h ago
Karyopharm Therapeutics Showcases Pipeline Advances and Upcoming Phase 3 Data in Cancer Therapies
Reuters · 6h ago
Karyopharm Q4 revenue rises on XPOVIO demand
Reuters · 8h ago
Karyopharm Therapeutics GAAP EPS of -$5.71 misses by $3.67, revenue of $34.08M beats by $0.92M
Seeking Alpha · 8h ago
Karyopharm Therapeutics Q4 EPS $(5.71) Misses $(1.99) Estimate, Sales $34.079M Miss $35.112M Estimate
Benzinga · 8h ago
*Karyopharm Therapeutics: Existing Liquidity, Including Cash, Cash Equivalents, Investments, Cash Flow From Net Pdt Rev and License and Other Rev Will Enable Co to Fund Current Operating Plans Into 2Q of 2026 >KPTI
Dow Jones · 8h ago
*Karyopharm Therapeutics Sees FY26 U.S. XPOVIO Net Pdt Rev $115M-$130M >KPTI
Dow Jones · 8h ago
More
About KPTI
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. It is developing and commercializing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead asset, XPOVIO (selinexor), is marketed in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. The Company is engaged in evaluating selinexor in certain hematological and solid tumor malignancies, including endometrial cancer, mycosis fungoides (MF) and diffuse large B-cell lymphoma (DLBCL). The Company’s product candidate, eltanexor, is an oral SINE compound like selinexor, that selectively blocks the nuclear export protein XPO1.

Webull offers Karyopharm Therapeutics Inc stock information, including NASDAQ: KPTI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KPTI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KPTI stock methods without spending real money on the virtual paper trading platform.